Novo Nordisk shares fall roughly 7% despite a second guidance raise

Novo Nordisk, the maker of Wegovy and Ozempic, raised its 2026 outlook on August 4, now expecting adjusted sales and operating profit to range from flat to down 6% at constant exchange rates, an improvement from the prior forecast of down 4% to 12% ^[1][2]. Despite the upgrade, shares fell roughly 7% ^[1][2]. The reaction shows investors are looking past the headline numbers a year into CEO Mike Doustdar's tenure ^[1].

The quarter's adjusted operating profit was 33.4 billion Danish crowns (about $5.15 billion), up 11% from a year earlier and above analyst forecasts of 28.74 billion crowns ^[1]. But analysts flagged that about DKK 2 billion of the quarter's sales came from rebate credits tied to prior periods, mostly connected to Ozempic pricing adjustments, not new demand ^[2]. Sales and distribution costs were also cut 13% during what the company itself calls its largest product launch, the Wegovy pill ^[2]. Take out both effects, and adjusted operating profit would have gone backward rather than grown ^[2]. Reported operating profit, which includes one-time items, actually fell 19%, and earnings per share fell 20%, after DKK 6.3 billion in pipeline impairment charges, including DKK 4.0 billion tied to the discontinued drug monlunabant ^[1].

The U.S. business, which drives most of Novo's profit, showed a split picture. Weekly U.S. injectable Wegovy prescriptions rose to about 310,000 from roughly 280,000 a year earlier, but U.S. Wegovy injectable sales fell 22% at constant currency, an accelerating decline ^[2]. Self-pay patients, who typically pay less per prescription, now make up about 35% of U.S. injectable Wegovy users, up from 10% to 15% a year ago ^[2]. Meanwhile, the Wegovy pill has passed 5 million U.S. prescriptions in its first 30 weeks, running at about 265,000 prescriptions a week and holding roughly 90% of the U.S. oral obesity drug market, compared with about 22,000 weekly prescriptions for the competing pill orforglipron ^[2]. Around 80% of pill patients had never taken a GLP-1 drug before ^[2].

Why it matters for patients

The gap between rising prescriptions and falling U.S. revenue reflects how much patients are now paying out of pocket, through self-pay channels or lower list prices, rather than through insurance at higher negotiated rates ^[2]. Novo has already announced it will cut U.S. list prices for Wegovy injections, Wegovy tablets, and Ozempic to $675 starting January 2027, cuts of roughly 50% and 35% respectively ^[2]. For patients, that could mean lower list prices ahead, though how that translates into copays depends on individual insurance plans.

Coverage access may also shift. Starting October 1, 2026, CVS Caremark, which covers about 26% of the U.S. market, will add other weight-loss medications to its largest formularies, ending Novo's prior exclusive position there ^[2]. That could open more competition and choice for patients whose insurance runs through CVS Caremark, though it is not yet known exactly how plan-level coverage will change.

What happens next

Novo's guidance itself implies a second-half 2026 sales decline of roughly 2% to 14% at constant currency ^[2]. A U.S. regulatory decision on the injectable diabetes and obesity drug CagriSema is expected by the end of 2026, following a trial in which it matched tirzepatide on weight loss but did not meet the bar on blood sugar control ^[2]. The list price cuts for Wegovy and Ozempic are set to take effect January 1, 2027 ^[2].